Fig. 6 | Signal Transduction and Targeted Therapy

Fig. 6

From: Nanobody-based chimeric antigen receptor T cells designed by CRISPR/Cas9 technology for solid tumor immunotherapy

Fig. 6

CD105 CAR-T cells efficiently inhibit growth of patient-derived xenograft (PDX) of hepatocellular carcinoma. a H&E staining tissue of primary tumor and PDX. The xenograft demonstrates morphology consistent with the original human tumor. The change of body temperature and weight (b, c n = 5) was calculated. The serum levels of IL-6 (d) was measured by ELISA (n = 5). e Growth curve of PDX (n = 5) treated with the CD19 or CD105 CAR-T cells at indicated time point. At the end of the experiment, the tumors treated with CD105 CAR-T cells were significantly smaller than CD19 CAR-T group. f CD105 CAR-T was incubated with CD105 protein for 30 min, tumor-bearing mice were injected with CD105 CAR -T cells in PDX models. The results show that the antitumor effect of CD105 CAR-T is reduced after incubated with CD105 protein

Back to article page